- You can view the full Vertex Ratings Report.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
The key issue for the FTC is whether the deal kills competition between Concert's treatment and Vertex's Kalydeco.
It's a wonder to me how split this market really is.
Here are Tuesday's top research calls, including new coverage of Adobe and Okta, a downgrade for Advanced Micro Devices and an upgrade for Chegg.